ARS Pharmaceuticals, Inc.SPRYNASDAQ
Loading
SPRY Revenue Growth (YoY Quarterly)•-67.56%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
-67.56%
-1539.2pp
-69.91%
-1212.7pp
-186.92%
-186.9pp
-187.86%
-187.9pp
-182.76%
-182.8pp
-182.35%
-182.4pp
-182.35%
-182.4pp
+0.63%
-1.2pp
+0.63%
-1.2pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +3043.40% | +1471.62% | -67.56% |
| Gross Profit Growth | +0.00% | +0.00% | +2046.60% | +1142.84% | -69.91% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | -186.92% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -187.86% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -182.76% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | -182.35% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | -182.35% |
| Weighted Average Shares Growth | +1.90% | +1.63% | +1.58% | +1.83% | +0.63% |
| Weighted Average Shares Diluted Growth | +1.90% | +1.63% | +1.58% | +1.83% | +0.63% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -203.53% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -204.28% |
| Receivables Growth | +1052.45% | +1562.46% | +4712.18% | +2841.97% | +176.65% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +988.39% | +60.57% |
| Asset Growth | +50.59% | +43.82% | +41.23% | +71.32% | -6.69% |
| Book Value per Share Growth | +9.21% | +0.64% | -12.04% | -27.85% | -55.78% |
| Debt Growth | -84.67% | -66.36% | +938.13% | +1401.96% | +230761.90% |
| R&D Expense Growth | -11.08% | -43.60% | -41.49% | -37.80% | +13.74% |
| SG&A Expenses Growth | +0.00% | +0.00% | +507.25% | +287.69% | +0.00% |
1 / 4